Kestra Medical Technologies Ltd

Despite a secular uptrend, a decisive support failure within the Stage 2 advance and declining momentum have shifted the medium-term bias to bearish. Price is now testing declining short EMAs and the 200 DMA, offering a structurally valid sell zone. Short-term timing favors execution as price rejects resistance, aligning with continuation of the corrective leg.

• ↑Q3 revenue rose 63% YoY to $24.6M; FY26 guidance raised to $93M
• ↑Gross margin expanded 9pp YoY to 52.6%, reflecting attractive unit economics
• ↓Q3 net loss widened to $34.2M from $21.8M, straining financials